Here’s a personal, non-exhaustive selection of highly awaited phase 3 trials that may shape practice within the next year – Paolo Tarantino

Merck announces positive results for KEYNOTE-756

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? – Paolo Tarantino

Incredibly excited to see our article on optimizing the safety of ADCs making it to the cover of the August issue of Nature Reviews Clinical Oncology!

The first oral SERD gets closer to Europe – Paolo Tarantino

In breast oncology there is a pre-TDXd & a post-TDXd era, with the latter still at the dawn – Paolo Tarantino

Can an oral, alopecia-free treatment improve outcomes for MBC vs paclitaxel? – Paolo Tarantino

Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs – Paolo Tarantino

The formatted version of the ESMO Consensus Statements on HER2-low breast cancer is finally published – Paolo Tarantino

ADCs keep showing impressive activity across cancers – Paolo Tarantino